Huyabio International Announces Global Clinical Trial Collaboration With Bristol Myers Squibb In Melanoma
HUYABIO International has announced a clinical collaboration with Bristol-Myers Squibb to conduct a Phase 3 trial evaluating the combination of HBI-8000 and Opdivo® (nivolumab) for treating unresectable or metastatic melanoma. Following a successful Phase 2 study that reported an overall response rate above 70%, this trial aims to further assess safety and efficacy. HBI-8000 is an epigenetic immunomodulator already approved for lymphoma and metastatic breast cancer in China.
- Successful Phase 2 study reported an overall objective response rate above 70% and disease control rate over 90%.
- Collaboration with Bristol-Myers Squibb may enhance credibility and support for further development.
- None.
SAN DIEGO, March 30, 2021 /PRNewswire/ -- HUYABIO International (HUYABIO™), the leader in accelerating global development of China's pharmaceutical innovations, today announced that it had entered into a clinical collaboration agreement with Bristol-Myers Squibb Company (NYSE: BMY) to evaluate the combination of HUYABIO's HBI-8000, an epigenetic immunomodifier, and Opdivo® (nivolumab), a PD-1 blocking antibody. The Phase 3 trial is designed to evaluate the safety and efficacy of the combination in subjects with unresectable or metastatic melanoma not previously treated with anti-PD-1 therapy.
"This Phase 3 trial follows our open label Phase 2 study which showed impressive clinical results for the combination of Opdivo and HBI-8000 to treat melanoma," said Dr. Mireille Gillings, CEO & Executive Chair of HUYABIO. "HBI-8000 has been shown to enhance the efficacy of Opdivo through one of its mechanisms of action that controls acetylation and nuclear transportation of PD-L1."
HUYABIO will be the sponsor of the trial. Bristol Myers Squibb will provide Opdivo clinical drug supply for the study. Opdivo® is a registered trademark of Bristol Myers Squibb.
About HBI-8000
HBI-8000 is an epigenetic immunomodulator approved for the treatment of lymphoma and metastatic breast cancer in China. This oral agent targets class I histone deacetylases causing cell cycle arrest and tumor cell death as the mechanism underlying its single agent activity against lymphoma. The drug also has immunomodulatory impact by increasing the efficacy of checkpoint inhibitors in preclinical animal models. The Company recently reported results from its ongoing Phase 2 study for the nivolumab combination demonstrating an overall objective response rate above
About HUYABIO International
HUYABIO is the leader in accelerating the global development of novel biopharmaceutical product opportunities originating in China enabling faster, more cost effective and lower-risk drug development in global markets. Through extensive collaboration with biopharmaceutical, academic and commercial organizations, it has built the largest China-sourced compound portfolio covering all therapeutic areas. With offices in the US, Japan, South Korea, Canada, Ireland and eight strategic locations across China, the Company has become a partner of choice to accelerate product development and maximize value globally. For more information, please visit www.huyabio.com.
Contact details:
Bob Goodenow, PhD
President
+1.858.342.2430
bgoodenow@huyabio.com
Yiota Merianos
Corporate Communications
+1.858.353.1217
ymerianos@huyabio.com
View original content:http://www.prnewswire.com/news-releases/huyabio-international-announces-global-clinical-trial-collaboration-with-bristol-myers-squibb-in-melanoma-301258139.html
SOURCE HUYABIO International
FAQ
What is the purpose of the Phase 3 trial involving BMY?
What were the results of the previous Phase 2 study related to BMY?
When was the collaboration between HUYABIO and BMY announced?
What is HBI-8000 in relation to BMY?
